News
Debates on reforming the global health architecture are entering a decisive phase. The Task Force led by the World Health Organization (WHO) is working intensively on its interim report. The report is due to be presented to the WHO Executive Board at the end of January 2027.
A central question the reforms throw up is what responsibilities the WHO should take on in the future and who gets to decide global health priorities. In a non-paper reported on by Devex, Germany’s Federal Ministry for Economic Cooperation and Development (BMZ), for example, argues for strengthening the WHO’s role in setting global health norms and standards. But at the same time, the BMZ wants to retain multi-stakeholder initiatives (MSIs) such as Gavi, the Vaccine Alliance, and the Global Fund to Fight AIDS, Tuberculosis and Malaria, and is considering extending their mandates to cover additional diseases.
The Geneva Global Health Hub (G2H2), which Global Policy Forum Europe is a member of, has weighed in on the debate with its policy paper on reforming the global health architecture, published in late October.
What G2H2 expects from the reform
The World Health Assembly has asked the Task Force to develop recommendations on responsibilities and mandates, coordination and inclusive decision-making and financing.G2H2 responds with four demands, the fourth going beyond the Task Force’s remit
1. Align the global health architecture with people’s health needs
Reform should start from what people actually need for their health, and the public functions required to meet those needs, not from existing institutions, their remits and their own interests. Take non-communicable diseases such as diabetes, cancer and cardiovascular disease: their prevention and treatment have so far received too little attention in global health funding and cooperation.
Closing these gaps in care requires strong public health systems, universal access to health services and essential medicines, reliable public funding for health and effective state structures for health planning, prevention, regulation and care.
The WHO must be strengthened as the central multilateral institution for developing binding and voluntary health norms and standards worldwide and coordinating international cooperation, in line with its mandate. These would cover, for example, disease prevention, diagnosis, treatment and the quality and safety of medicines. At the same time, countries and regions need more decision-making power, resources and capacity of their own.
In practice, international funding commitments must be more closely aligned with national health strategies, rather than being used to build parallel programmes and administrative structures. Investment in primary health care, health workers and public health infrastructure must take priority. Countries must also have more opportunities to build up their own capacity for research, production and care.
2. Ensure democratic accountability and participation in global health decisions and limit private influence
WHO member states must ensure that decisions across the global health architecture are transparent, democratically legitimate and made with substantial participation by civil society, health workers and affected communities.
Voices from low- and middle-income countries and marginalised groups, in particular, should carry more weight. This includes, for example, involving these groups early on in developing strategies and setting priorities.
There must also be binding rules on transparency and accountability, a public lobbying register and effective safeguards against conflicts of interest and commercial influence. The provisions of the WHO’s Framework of Engagement with Non-State Actors (FENSA) should apply as a minimum standard across the global health architecture and be consistently implemented.
3. Strengthen public financing and base global health financing on solidarity
G2H2 calls for an end to global health financing’s dependence on voluntary, earmarked contributions from individual donors. Instead, it argues for more reliable public funding, with countries increasing their assessed contributions to international organisations. Funding should be more closely aligned with national health strategies. Its proposals also include debt cancellation, international tax cooperation and health-related levies.
Public funders must attach conditions to their investments in research and innovation to ensure affordable access, technology transfer and fair licensing.
4. Health policy must go beyond the health sector
The causes of health inequalities often lie outside health systems. Poverty, social inequality, environmental destruction, dietary and consumption patterns and economic and legal frameworks all play a major part in shaping the conditions in which people can lead healthy lives.
G2H2 therefore calls for a comprehensive approach to health policy that also takes in tax law, consumer protection, income security and environmental law. It must be possible to hold companies accountable when their activities cause health or environmental harm across borders.
G2H2 also calls for a clearer definition of what a “Global Public Health Good” is. The World Health Assembly should commission the WHO to develop guidelines on this. Among other things, these should ensure that the political recognition of vaccines and vaccination programmes as global public goods doesn’t remain an empty gesture for lack of binding rules on financing, access and distribution.
The G2H2 policy paper shares concerns with other reform initiatives. These include regional dialogues on global health reform, supported by the Wellcome Trust, and HEAR CSO, a civil society initiative developing proposals for reforming the global health architecture.
But G2H2 goes further in its political demands. It places more emphasis on regulating commercial interests, strengthening public financing and establishing the legal conditions for health equity. It shares the Accra Reset initiative’s goals of strengthening health sovereignty and regional capacities and overcoming external dependencies.”
The crisis is human-made and can therefore be changed
What people have constructed, people can change.’ That’s how Winnie Byanyima, Executive Director of UNAIDS, put it at the World Health Summit. In her view, the crisis of the global health system is the result of political decisions, social power relations and unjust economic structures.
Byanyima wants inequality put at the heart of global health policy. When girls have no access to education, when women can’t make decisions about their own bodies, when children have no chance of a healthy life, these, she argues, are the results of political and institutional choices.
The same inequalities run through the global health architecture. Low- and middle-income countries are responsible for their populations’ health, yet they often have only a limited say in the decisions and priorities of international health initiatives and major donors from the Global North
“It’s therefore not enough, as experts from academia and civil society point out, to hand these countries more responsibility for implementing global health programmes. They need to be able to set their own health policy priorities and shape their own health systems. That’s why G2H2 is calling for a reform that shifts decision-making power and resources back to countries and the needs of their populations.
The big pharmaceutical companies’ ideas for reform, by contrast, leave existing power relations and structural inequalities in the global economy unchallenged. At the same summit, Harmony P. Garges, Chief Global Health Officer at GSK (formerly GlaxoSmithKline), set a different benchmark: “The true test of reform is not where power is located or whether the power is shared. But the true test of reform will come when we see people living better lives and having better health.”
Contradictions in the BMZ non-paper: strengthening the WHO or entrenching parallel power structures?
These differing visions for the future of the global health architecture aren’t just playing out between industry and civil society. They’re also being debated within the German government. What’s puzzling about the BMZ’s non-paper on global health, reported on by Devex, isn’t only what it says, but that it apparently sets out a separate BMZ position. That raises questions about coordination with the Federal Ministry of Health (BMG). The lack of an agreed government position on the reform process is all the more surprising given that Germany, represented by Björn Kümmel from the BMG, co-chairs the Task Force with China.
Here’s the contradiction: the BMZ wants to strengthen the WHO and its role in setting health norms, while holding on to MSIs such as Gavi and the Global Fund. It’s even considering extending their mandates to cover more diseases.
That’s a problem for several reasons. Multi-stakeholder initiatives aren’t simply extra funding instruments. They have increasingly taken on policy-steering and decision-making functions too. Their governing bodies include not only governments but also companies and private foundations, which gives these actors influence over global health priorities and how public money is spent.
There’s often little transparency about how these initiatives are funded and how effective they are, and little democratic accountability to parliaments and affected populations. The result: a small number of wealthy actors from the Global North shape the priorities, while health ministries, particularly in the Global South, are saddled with extra, parallel administrative and reporting requirements.
These initiatives have also helped shift responsibilities and decisions away from the multilateral institutions that are actually supposed to handle them, as the example of the Access to COVID-19 Tools Accelerator (ACT-A) clearly shows. As a result, they compete with the WHO for scarce public funding and weaken its role in steering policy.
There’s also a risk that the political causes of health problems get pushed into the background. Instead of changing unjust trade and patent systems or closing regulatory gaps, the solutions on offer often rely on medical and technological measures such as medicines and vaccines, on financial incentives for companies to develop and supply them, and on voluntary commitments to make health products affordable and accessible.
The BMZ paper also refers to the Accra Reset initiative and, like it, calls for greater African ownership and sovereignty and an end to external dependencies. But continuing and expanding parallel structures dominated by donors and the private sector, as the BMZ envisages, contradicts these aims.
Another contradiction lies in the proposal for a new high-level mechanism to provide “stewardship” and make recommendations on future global health challenges. This risks creating yet another governance structure, with responsibilities that could overlap with the WHO’s. The BMZ paper also leaves open whether the new mechanism would sit within the UN system, which raises further questions.
What the Task Force must recommend in its interim report
The Task Force met again on 16 November to continue work on its interim report. Its recommendations will have to bring these different perspectives together. But they need to do more than simply reshuffle existing institutions and get them to coordinate better. Above all, they should address existing power relations, democratic accountability and the influence of private actors, and strengthen public financing for global health.
